



(51) International Patent Classification:

C07D 243/12 (2006.01) **C07D 495/04** (2006.01)
C07D 401/12 (2006.01) **C07D 471/04** (2006.01)
C07D 401/14 (2006.01) **C07D 513/04** (2006.01)
C07D 491/04 (2006.01) **C07D 413/14** (2006.01)
C07D 405/14 (2006.01) **A61K 31/551** (2006.01)
C07D 417/14 (2006.01) **A61P 9/06** (2006.01)
C07D 409/14 (2006.01)

(21) International Application Number:

PCT/JP2009/053623

(22) International Filing Date:

20 February 2009 (20.02.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2008-041296 22 February 2008 (22.02.2008) JP
 2008-227368 4 September 2008 (04.09.2008) JP

(71) **Applicant** (for all designated States except US): **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 9, Kanda-Tsukasamachi 2-chome, Chiyoda-ku, Tokyo, 1018535 (JP).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **OSHIMA, Kunio** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **OSHIYAMA, Takashi** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **TAIRA, Shinichi** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **MENJO, Yasuhiro** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **YAMABE, Hokuto** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **MATSUMURA, Shuuji** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **UEDA, Masataka** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **KOGA, Yasuo** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO.,

LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **TAI, Kuninori** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **NAKAYAMA, Sunao** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **ONOGAWA, Toshiyuki** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **TSUJIMAE, Kenji** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(74) **Agents:** **Saegusa & Partners** et al.; Kitahama TNK Building, 1-7-1, Doshomachi, Chuo-ku Osaka-shi, Osaka 5410045 (JP).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION

(57) **Abstract:** The present invention provides a novel benzodiazepine compound that blocks the I_{Kw} current or the Kv1.5 channel or the IKACH current (the GIRK1/4 channel) potently and more selectively than other K^+ channels. The benzodiazepine compound of the invention is represented by General Formula (1) wherein R^1 , R^2 , R^3 , and R^4 are each independently hydrogen or lower alkyl; R^2 and R^3 may be linked to form lower alkylene; A^1 is lower alkylene optionally substituted with one or more hydroxy; and R^5 is group represented by wherein R^6 and R^7 are each independently hydrogen or organic group; X_A and X_B are each independently bond, lower alkylene, etc.

